Evidence map›Paper›PMID 29987206›Full record

ReviewMaterials (Basel, Switzerland)2018

Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview.

Ernesto Palma, Antonella Pasqua, Agnese Gagliardi, Domenico Britti, Massimo Fresta, Donato Cosco

Open access · goldAbstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Current pharmaceutical biotechnology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Amphotericin B Loaded Polymeric Nanoparticles for Treatment ofNanomaterials (Basel, Switzerland) · 2020
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Ernesto PalmaDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", Viale S. Venuta, I-88100 Catanzaro, Italy. palma@unicz.it.
Antonella PasquaDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", Viale S. Venuta, I-88100 Catanzaro, Italy. antonellapasqua@unicz.it.
Agnese Gagliardi
Domenico BrittiDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", Viale S. Venuta, I-88100 Catanzaro, Italy. gagliardi@unicz.it.
Massimo FrestaDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", Viale S. Venuta, I-88100 Catanzaro, Italy. fresta@unicz.it.
Donato CoscoDepartment of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", Viale S. Venuta, I-88100 Catanzaro, Italy. donatocosco@unicz.it.ORCID 0000-0002-4898-0365
Magna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, nanotechnology has made phenomenal strides in the pharmaceutical field, favouring the improvement of the biopharmaceutical properties of many active compounds. Many liposome-based formulations containing antitumor, antioxidant and antifungal compounds are presently on the market and are used daily (for example Doxil

Indexed as

amphotericin Bcolloidsdrug deliveryLeishmaniananoparticlesPLGA

Identifiers

PMID29987206
PMCPMC6073796
OpenAlexW2829142499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.